Clinical Trials
338 trialsMK-4280A-007
Merck Sharp & Dohme LLC
SafeHeal Anastomosis Feasibility Evaluation (SAFE)-2023 Study
SafeHeal Inc
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
LEAP-005
Merck Sharp & Dohme LLC
NAUTICALCRC
Pierre Fabre Medicament
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
Inspirna, Inc.
Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer
BeOne Medicines
RECITE
Amgen
MK-7902-017
Merck Sharp & Dohme LLC
DESTINY-CRC02
Daiichi Sankyo
CAPSTAN CRC
Pierre Fabre Medicament
PREEMPT CRC
Freenome Holdings Inc.
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen Inc.
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
CheckMate 9N9
Bristol-Myers Squibb
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
Merck Sharp & Dohme LLC
QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
NantCell, Inc.
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Alaunos Therapeutics
ConsortiumIO
Vedanta Biosciences, Inc.
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Eisai Inc.
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
CheckMate 8HW
Bristol-Myers Squibb
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
CLAUDE
Enterome
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
AMPLIFY-201
Elicio Therapeutics
GLIMMER-01
Palleon Pharmaceuticals, Inc.
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
Sotio Biotech Inc.
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
Bristol-Myers Squibb
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Hutchmed
SAFE-2
SafeHeal Inc
ELEVATE CRC
Gilead Sciences
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
Nektar Therapeutics
ARROW
Hoffmann-La Roche
PROACC-1
Pfizer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer
Daiichi Sankyo
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
Mirror Biologics, Inc.
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
C-PRECISE-01
Menarini Group
MasterKey-01
Black Diamond Therapeutics, Inc.